Status:
COMPLETED
Toclizumam Versus Dexamethasone in Severe Covid-19 Cases
Lead Sponsor:
South Valley University
Conditions:
Pneumonia, Viral
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
randomized controlled trial comparing survival benefit of Tocilizumab therapy with dexamethasone in patients with severe COVID 19
Detailed Description
The current study takes place in the ICU of ESNA hospital, the first COVID-19 quarantine hospital in Egypt, located in Upper Egypt, Luxor governorate during the period from March 2020 to June 2020. T...
Eligibility Criteria
Inclusion
- respiratory rate \> 30 cycle/minute, Bilateral CT infiltration \> 30%, PaO2/FiO2 ratio \<150 or saturation \<90 on \>6L/min, Two positive laboratory tests of: (CRP\>100 g/dL, lymphocytes\<600 /mm3, D dimer\>L, Ferritin \>500)
Exclusion
- Pediatric patients \< 18 years old, patients with active bacterial or fungal infection and patients who were not requiring supplemental oxygen
Key Trial Info
Start Date :
March 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 5 2020
Estimated Enrollment :
69 Patients enrolled
Trial Details
Trial ID
NCT04519385
Start Date
March 1 2020
End Date
August 5 2020
Last Update
August 25 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qena faculty medicine
Qina, Egypt, 83523